Eosinophilic chronic sinusitis
Conditions
Interventions
non-ECRS:none
control:none
ECRS:none
Sponsors
Hangzhou First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. ECRS Group: (1) Meets the ECRS diagnostic criteria in the "Guidelines for the Diagnosis and Treatment of Chronic Rhinosinusitis (2024)": nasal endoscopy shows nasal polyps/mucosal edema, sinus CT Lund-Mackay score >= 12, proportion of eosinophilic infiltration in nasal mucosa tissue >= 10%; (2) Age 18-85 years, any gender; (3) Voluntarily participate in the study and sign the informed consent form. 2. non-ECRS Group: (1) Meets the diagnostic criteria for chronic rhinosinusitis, but the proportion of eosinophilic infiltration in nasal mucosa tissue < 10%; (2) Other inclusion criteria are the same as those for the ECRS group. 3. Healthy Control Group: (1) Undergoing nasal surgery due to nasal septum deviation, nasal trauma, etc., and preoperative examinations (nasal endoscopy, CT) exclude sinusitis, rhinitis, and other nasal inflammatory diseases; (2) Age 18-65 years, any gender; (3) Voluntarily participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. All groups must exclude: (1) Use of hormonal drugs within 2 weeks (including nasal glucocorticoid sprays, oral/intravenous hormones, etc.); (2) Acute sinusitis or upper respiratory tract infection (such as cold, acute rhinitis, etc.) within 2 weeks; (3) Pregnant or lactating women, or those planning to become pregnant during the study; (4) Presence of severe systemic diseases such as severe liver or kidney dysfunction, cardiovascular or cerebrovascular diseases, malignant tumors, immune deficiencies (e.g., HIV infection); (5) Contraindications to examinations involved in this study (such as nasal mucosal biopsy, blood tests); (6) Nasal/nasal sinus surgery within 6 months (excluding diagnostic nasal mucosal biopsy); (7) History of drug abuse or psychiatric disorders that prevent cooperation with the study procedures. 2. Additional exclusions for the ECRS and non-ECRS groups: (1) Presence of other allergic/Type 2 inflammation-related diseases such as asthma, allergic rhinitis, allergic conjunctivitis; (2) Presence of nasal benign or malignant tumors, nasal polyps (for the ECRS group, nasal polyps are a diagnostic criterion and not excluded), ciliary motility disorders, etc. 3. Additional exclusions for the healthy control group: (1) History or current presence of nasal inflammatory diseases such as sinusitis, rhinitis, or nasal polyps; (2) Presence of allergic diseases (such as atopic dermatitis, food allergies, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High Mobility Group Box 1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of Eosinophils in Nasal Mucosa;Nasal Polyp Score;Lund-Mackay CT Score;Visual Analogue Scale;Sino-Nasal Outcome Test-22;Peripheral Blood Eosinophil Count; | — |
Countries
China
Contacts
Public ContactJing Li
Hangzhou First People's Hospital
Outcome results
None listed